PharmAust’s MND trial successfully completes third patient cohort – Nokturnal
PharmAust Limited (ASX: PAA) has completed its third cohort of six participants in its Phase 1/2 clinical trial of its lead drug candidate monepantel (MPL) in Motor Neurone Disease/Amyotrophic Lateral Sclerosis (MND/ALS). The company has now completed the day 28 dosing of the final patient in the third cohort. Importantly, all participants from Cohorts 1, … Read more